Understanding how mutant p53 proteins accumulate in cancer and exploring new treatment options.
The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential
This study is looking into how certain faulty proteins in colorectal cancer can help tumors grow, and it aims to find out how these proteins stick around longer than they should, which could lead to new treatments for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10852976 on NIH RePORTER |
What this research studies
This research investigates the accumulation of mutant p53 proteins in colorectal cancer, which can contribute to tumor growth. The study aims to uncover the mechanisms behind this accumulation, particularly focusing on the role of MDM2B, a protein that regulates p53. By understanding how these mutant proteins become stable and promote cancer, the research seeks to identify new therapeutic strategies that could effectively target cancers with mutant p53. Patients may benefit from potential new treatments developed from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer that has mutations in the p53 gene.
Not a fit: Patients with colorectal cancer that does not involve p53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for colorectal cancer patients with mutant p53, improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in targeting mutant p53 proteins, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Feng, Zhaohui — Rutgers Biomedical and Health Sciences
- Study coordinator: Feng, Zhaohui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.